Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Taran S. Lundgren"'
Autor:
Athena L. Russell, Chengyu Prince, Taran S. Lundgren, Kristopher A. Knight, Gabriela Denning, Jordan S. Alexander, Jaquelyn T. Zoine, H. Trent Spencer, Shanmuganathan Chandrakasan, Christopher B. Doering
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss , Pp 710-727 (2021)
Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks associated with this approach center on the requirement for pre-transplantation conditioning
Externí odkaz:
https://doaj.org/article/b389bd2ba16049b3ab15cefbbc027227
Autor:
Seema R. Patel, Taran S. Lundgren, Wallace Hunter Baldwin, Courtney Cox, Ernest T. Parker, John F. Healey, Ryan P. Jajosky, Patricia E. Zerra, Cassandra D. Josephson, Christopher B. Doering, Sean R. Stowell, Shannon L. Meeks
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germi
Externí odkaz:
https://doaj.org/article/470104dc411c45558fc574d5808a9c73
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Neutralizing antibodies to factor VIII (fVIII), referred to as “inhibitors,” remain the most challenging complication post-fVIII replacement therapy. Preclinical development of novel fVIII products involves studies incorporating hemophilia A (HA)
Externí odkaz:
https://doaj.org/article/6d51a5d92425473fac5229032f60f244
Autor:
Jordan S. Alexander, Athena Liza Russell, Kristopher A. Knight, Jaquelyn T. Zoine, Gabriela Denning, Chengyu Prince, Christopher B. Doering, Taran S. Lundgren, H. Trent Spencer, Shanmuganathan Chandrakasan
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss, Pp 710-727 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss, Pp 710-727 (2021)
Hematopoietic stem and progenitor cell (HSPC) lentiviral gene therapy is a promising strategy toward a lifelong cure for hemophilia A (HA). The primary risks associated with this approach center on the requirement for pre-transplantation conditioning
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51cb314a406f4239e729f4eb6dc60ca6
https://doi.org/10.1016/j.omtm.2021.04.016
https://doi.org/10.1016/j.omtm.2021.04.016
Autor:
Taran S. Lundgren, Gabriela Denning, Sean R. Stowell, H. Trent Spencer, Christopher B. Doering
Publikováno v:
Blood advances. 6(8)
Advances in the development of novel treatment options for hemophilia A are prevalent. However, the anti–factor VIII (FVIII) neutralizing antibody (inhibitor) response to existing FVIII products remains a major treatment challenge. Although some no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::418ac2d0c2f9c3a0e094865b10113c74
https://pubmed.ncbi.nlm.nih.gov/35286375
https://pubmed.ncbi.nlm.nih.gov/35286375
Autor:
Brent A. Uhrig, Taran S. Lundgren, Nathaniel Huebsch, Joel D. Boerckel, Robert E. Guldberg, Gordon L. Warren, Mon-Tzu A. Li, Nick J. Willett
Publikováno v:
Tissue Engineering Part C: Methods. 19:316-325
Extremity injuries involving large bone defects with concomitant severe muscle damage are a significant clinical challenge often requiring multiple treatment procedures and possible amputation. Even if limb salvage is achieved, patients are typically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c21a19a7d24b7351e6ade29dbc6c44
https://doi.org/10.1089/ten.tec.2012.0290
https://doi.org/10.1089/ten.tec.2012.0290